

Curriculum vitae

Personal data

Surname Lisman
First names Johannes Antonius (Ton)
Date of birth March 10th, 1976
Nationality Dutch
Email j.a.lisman@umcg.nl
Homepage <http://www.rug.nl/staff/j.a.lisman/>

Work experience

January 2015 – present

Full Professor of Experimental Surgery, Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, The Netherlands

June 2009 – December 2014

Tenure track (associate) Professor of Experimental Surgery, Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, The Netherlands

January 2008-December 2008

Interim head of the Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, The Netherlands

February 2007-May 2009

Assistant Professor, Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, The Netherlands (in a tenure track program)

January 2003-February 2007

Assistant professor, Thrombosis and Haemostasis Laboratory, University Medical Center Utrecht, The Netherlands

Education

1999-2002

PhD Student, Thrombosis and Haemostasis Laboratory, University Medical Center Utrecht, The Netherlands

Title of dissertation: Haemostatic effects of recombinant factor VIIa
Supervisors: Prof. Dr. Ph.G. de Groot, Dr. H.K. Nieuwenhuis
PhD received: December 17th, 2002. (*Cum laude*)

1994-1998

Master of Science training program, Chemistry Faculty, Utrecht University, The Netherlands

Area of research

I am one of the few experts worldwide on clinical and fundamental research on bleeding and thrombosis in patients with liver diseases.

In the past decade, through a combination of careful analysis of the clinical phenotype of these patients and in-depth laboratory analyses, my group has been able to redefine the clinical consequences of hemostatic changes associated with liver diseases. In particular, we demonstrated that patients with chronic and acute liver diseases are in a hemostatic ‘rebalance’ due to a concomitant decline in pro- and antihemostatic forces (summarized in *Blood* 2010;116(6):878-85). These novel insights have had profound consequences for clinical management, and have led to world-wide changes in the approach to treatment and prevention of bleeding in patients with liver diseases (*Transfus Med Rev.* 2014 Jul;28(3):107-13).

In 2009, I initiated a more fundamental research line aimed at elucidating molecular mechanisms behind blood platelet-mediated stimulation of liver regeneration. Work in experimental animal models suggested a pivotal role for blood platelets in supporting liver regeneration (*Science* 2006;312(5770):104-7). My group has also provided evidence that platelets support liver regeneration in humans (*Ann Surg.* 2010;251(2):300-6), and have identified functional platelet RNA transfer to hepatocytes as a key factor in platelet-mediated hepatocyte proliferation (*Blood.* 2015;126(6):798-806).

PhD Graduates

- Wilma Potze 24/4/2017 – Hemostasis and anticoagulant therapy in liver diseases
- Edris Alkozai 2/12/2016 – Factors associated with outcome of liver surgery and hepatocellular carcinoma
- Freeha Arshad 7/9/2016 - Management of hemostatic alterations in cirrhosis and liver transplantation
- Anne Marieke Schut 8/6/2016 – Coagulation factor VIIa: prohemostatic drug and biomarker for thrombosis
- Andrie C. Westerkamp 24/2/2016 – Strategies to improve outcome after transplantation of extended criteria donor livers
- Marieke de Boer 10/6/2015 – Impact of Hemostasis and Blood Loss on Outcome after Liver Surgery
- Michael Sutton 18/11/2013 – Studies on injury and repair of donor bile ducts after liver transplantation
- Sanna op den Dries 13/11/2013 – Bile duct injury in liver transplantation
- Ilona Pereboom 8/9/2010 – Blood platelets in liver transplantation – clinical studies on the function of blood platelets and primary hemostasis during and after liver transplantation
- Mirjam Meltzer 17/6/2010 – The role of the fibrinolytic system in venous and arterial thrombosis
- Nienke Warnaar 12/10/2009 – Thrombotic complications in Liver Transplantation
- Cees Weeterings 23/6/2009 – The interplay between platelets and coagulation
- Arienne van Marion 5/10/2006 – Different aspects of thalidomide treatment and stem cell transplantation in multiple myeloma patients
- Jan Heyligers 29/9/2006 – Novel strategies to improve the patency of vascular prostheses

Scientific awards

- 1999, 2001, 2003 – Young Investigator Awards at the biannual Meeting of the International Society of Thrombosis and Haemostasis, Washington D.C, USA (1999), Paris, France (2001), Birmingham, UK (2003).
- 2001 – Novo Nordisk Haemostasis Award for excellent achievement in unravelling the mechanism of action of recombinant coagulation factor VIIa (15.000 Euro).
- 2010 – UMCG Research grant (100.000 Euro)
- 2011 – Jan van der Meer research grant (25.000 Euro)

Patents

- 2006 – Antithrombotic activities of peptides inhibiting the interaction between von Willebrand factor and collagen type III (together with Prof. Dr. Ph. G. de Groot, UMC Utrecht, The Netherlands, and Dr. R.W. Farndale, University of Cambridge, U.K.).
- 2007 – Factor VII polypeptides with increased affinity to platelets (together with Prof. Dr. Ph. G. de Groot, UMC Utrecht, The Netherlands, and Novo Nordisk A/S, Denmark).

Awarded grant applications.

- 2003 – Dutch Thrombosis Foundation. 'Identification of a receptor involved in fibrin-mediated aggregation of platelets independent of integrin α IIb β 3'. €106.287. Principal investigator
- 2004 – NWO, VENI. 'Mechanisms behind platelet adhesion and aggregation independent of integrin α IIb β 3'. €200.000. Principal investigator
- 2005 – European Haematology Association Research Fellowship. 'Hypofibrinolysis and the risk of a first episode of venous thrombosis'. €65.000. Principal investigator
- 2005 – Dutch Heart Foundation. 'Hypofibrinolysis as a risk factor for venous and arterial thrombosis'. €193.828. Principal investigator
- 2005 – Dutch Heart Foundation. 'Identification and structural analysis of von Willebrand factor binding sites in collagen using triple-helical peptides: New opportunities for antithrombotic therapy?'. €190.980 (co applicant)
- 2006 – Unrestricted research grant Novo Nordisk A/S, Denmark. 'Mechanism of action of recombinant factor VIIa'. €225.000. Principal investigator
- 2006 – Dutch Heart Foundation. 'Active conformation of von Willebrand factor in the development of thrombotic complications'. €199.909 (co-applicant)
- 2006 – UMC Utrecht collaborative research project grant. 'Role of *Staphylococcus aureus* protein SSL5 in platelet activation' Collaboration with Dr. C. de Haas, Dept. Microbiology, UMC Utrecht, The Netherlands. €65.000
- 2007 – European Society for Organ Transplantation – Senior Basic Science Grant. 'Platelets and platelet-derived serotonin in liver transplantation – do the beneficial consequences outweigh the detrimental effects?'. €40.000. Principal investigator
- 2007 – Roche Organ Transplantation Research Foundation. The role of platelets in organ damage in the brain dead donor. Of the 300.000 (€190.000) Swiss francs requested, 100.000 have been granted, the remaining 200.000 have been provisionally approved, pending data supporting proof of principle for the application. Principal investigator
- 2009 – Dutch Thrombosis Foundation. 'Modulation of coagulation by glycoprotein Iba – a study using nanodisc technology. €121.762, Principal investigator
- 2009 – Access to Insight Basic Research Grant (Novo Nordisk). 'Modulation of thrombin generation by glycoprotein Iba – a study using nanodisc technology. €70.000, Principal investigator
- 2010 – Stichting Tekke Huizinga Fonds. 'Transfusion policy in patients with complex changes of hemostasis – a rebalanced hemostatic status in patients with acute liver failure?' €16.800. Principal investigator.

- 2010 – NWO, VIDI. ‘Molecular mechanisms involved in blood platelet-mediated liver regeneration’. €860.000. Principal investigator.
- 2010 – Novo Nordisk unrestricted educational grant. ‘Studies on the Mechanism of Action of the prophylactic activity of recombinant factor VIIa in haemophilia inhibitor patients. €164.000. Principal investigator.
- 2013 – Stichting Tekke Huizingafonds. ‘Efficacy of pro- and antihemostatic drugs in plasma from patients with liver disease’ €14.940. Principal investigator.
- 2015 – Stichting Tekke Huizingafonds. ‘The hemostatic status of critically ill patients with liver disease’ €15.000. Principal investigator.
- 2015 – Dutch Thrombosis Foundation. ‘Regulating autophagy: a novel antithrombotic strategy?’ €154.432. Principal investigator.
- 2015 – Grifols Antithrombin Research Award. ‘Antithrombin: a new therapeutic strategy to reduce progression of liver disease?’ €50.000. Principal investigator.

Editorships, editorial boards, tasks in (inter)national societies

2014 – present	Associate Editor , Journal of Thrombosis and Haemostasis
2015 – present	Senior Editor , Seminars in Thrombosis and Haemostasis
2014 – 2018	Member of the Council (class 2018), International Society of Fibrinolysis and Proteolysis
2013 – 2014	Editorial Board Member , Journal of Thrombosis and Haemostasis
2012 – present	Editorial Board Member , F1000 Research
2011 – present	Grants Review Committee Member , NWO TOP grants, Netherlands Organisation for Scientific Research
2011 – present	Member of F1000 Faculty , section Bleeding and Coagulation Disorders
2008 – 2012	Advisory Board Member , Journal of Thrombosis and Haemostasis

Peer review

Reviewer for various journals including *Blood*, *Journal of Thrombosis and Haemostasis*, *Thrombosis and Haemostasis*, *Hepatology*, *Journal of Hepatology*, *Liver International*, *Liver Transplantation*, *British Journal of Surgery*

International conference organisation

- **Organiser** of the 7th international symposium on Coagulation in Liver Disease Rome, Italy, 6-7 October 2017
- **Organiser** of the 6th international symposium on Coagulation in Liver Disease Charlottesville, VA, USA, 3-4 October, 2015
- **Organiser** of the 5th international symposium on Coagulation in Liver Disease Padua, Italy, 27-28 September 2013
- **Advisory committee member** of the 24th congress of the International Society of Thrombosis and Haemostasis, Amsterdam, 29 June - 4 July, 2013
- **Advisory committee member** of the 21st international congress on Fibrinolysis and Proteolysis, Brighton UK, 1-5 July 2012
- **Organiser** of the 4th international symposium on Coagulation in Liver Disease London, UK, 29-30 September 2011
- **President** of the 3rd international symposium on Coagulation in Liver Disease Groningen, 18-19 September 2009

Education and outreach

- 2013 – 2016 **Chair ‘Medische Publieksacademie’ UMCG** – organisation of lectures on medical topics given by doctors and scientists from the UMCG specifically aimed at the lay public.
- 2009 – present **Mentor and lecturer** within the bachelor curriculum of medicine and the Junior Scientific Masterclass of the UMCG (<https://jsm Groningen.nl/>)
- 2003 – present **Regular lecturer on national and international courses on thrombosis and haemostasis** (Dutch Heart Foundation; Dutch Society on Thrombosis and Haemostasis; European Society of Organ Transplantation; European Association for the Study of Liver Disease).

International Collaborations

- Since 2014, I am a consulting member of the **United States Acute Liver Failure Study Group** (<http://www.utsouthwestern.edu/labs/acute-liver/about/>), a large consortium aimed at collecting data and clinical samples from patients with this rare disease and to perform multi-center clinical trials.
I specifically collaborate with **Dr. William Lee** (Southwestern Medical Center, Texas, USA), and **Dr. R. Todd Stravitz** (VCU, Richmond, USA).
- **Dr. Stephen H. Caldwell** and **Dr. Patrick G. Northup** (Dept. of Hepato-Gastroenterology, University of Virginia, Charlottesville, USA): collaboration on hemostasis and thrombosis in patients with cirrhosis
- **Dr. Arun Sanyal** (VCU, Richmond, USA): collaboration on hemostasis in patients with fatty liver disease.
- **Dr. Peter J. Lenting** (INSERM U770, Le Kremlin Bicetre, France): Long-time collaboration on von Willebrand factor.
- **Dr. Robert Ariens** (University of Leeds, UK): collaboration on the study of fibrin structure in clinical samples.
- **Dr. William Bernal** (King’s College Hospital, London, UK): collaboration on hemostasis in critically ill patients with liver diseases.
- **Dr. James P. Luyendyk** (Michigan State University, East Lansing, USA): collaboration on intrahepatic activation of coagulation in progression of liver diseases.

Study Visits

- 2005 **Visiting researcher**, Thrombosis and Haemostasis Section, The Baylor College of Medicine, Houston, TX, USA (6 months)
This has resulted in multiple collaborative studies on platelets, von Willebrand factor, and ADAMTS13 (Dr. J.F. Dong and Dr. J.A. Lopez, who both have moved to the Puget Blood Center in Seattle).
- 2002 - present **Visiting researcher**, University of Virginia, Charlottesville VA, USA; Virginia Commonwealth University, Richmond VA, USA (to discuss ongoing projects with Caldwell, Northup, Lee, Stravitz, Sanyal – *see details below*) on a regular basis (1-2 times a year, for ~1 week).
- 2000 - 2001 **Visiting PhD researcher**, - During my PhD training, I worked at the Laboratory of the Research and Development Group of Novo Nordisk A/S (a pharmaceutical company in Copenhagen, Denmark), which resulted in a joint publication, a joint patent, and a collaboration which is still active.

International Consulting

2005 – 2010 Consultant for Novo Nordisk A/S, Denmark.

Membership of Scientific Societies

- International Liver Transplant Society (2013-present)
- International Society of Fibrinolysis and Proteolysis (2012 – present)
- Dutch society of Hepatology (2010 – present)
- European Society of Organ Transplantation (ESOT) (2007 – present)
- European Haematology Association (EHA) (2004 – present)
- International Society of Thrombosis and Haemostasis (ISTH) (2003 – present)
- Dutch Society of Thrombosis and Haemostasis (NVTH) (1999 – present)

Publications

For an updated list see: <http://www.ncbi.nlm.nih.gov/pubmed/?term=lisman+t>

1. Horbach DA, van Oort E, Lisman T, Meijers JC, Derksen RH, de Groot PG. Beta2-glycoprotein I is proteolytically cleaved in vivo upon activation of fibrinolysis. *Thromb Haemost.* 1999; 81:87-95.
2. Lisman T, Leebeek FW, Mosnier LO, Bouma BN, Meijers JC, Janssen HL, Nieuwenhuis HK, de Groot PG. Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. *Gastroenterology.* 2001; 121:131-139.
3. Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JCM, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. *Thromb Haemost.* 2001; 86:1035-1039.
4. Lisman T, Mosnier LO, Lambert T, Mauser-Bunschoten EP, Meijers JCM, Nieuwenhuis HK, de Groot PG. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A. *Blood.* 2002; 99:175-179.
5. Lisman T, Leebeek FWG, Meijer K, van der Meer J, Nieuwenhuis HK, de Groot PG. Recombinant Factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation. *Hepatology.* 2002; 35:616-621.
6. Lisman T, Leebeek FWG, de Groot PG. Haemostatic abnormalities in patients with liver disease. *J Hepatol.* 2002; 37:280-287.
7. Lisman T, Moschatsis S, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Recombinant factor VIIa enhances deposition of platelets with congenital or acquired alpha IIb beta 3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation. *Blood.* 2003; 101:1864-1870.
8. Meijer K, Hendriks HG, de Wolf JT, Klompaker IJ, Lisman T, Hagens AA, Slooff MJ, Porte RJ, van der MJ. Recombinant factor VIIa in orthotopic liver transplantation: influence on parameters of coagulation and fibrinolysis. *Blood Coagul Fibrinolysis.* 2003; 14:169-174.
9. Lisman T, de Groot PG. Rebuttal to: Effect of heparin on TAFI-dependent inhibition of fibrinolysis. *J Thromb Haemost.* 2003; 1:200-201.
10. Lisman T, de Groot PG. Mechanism of action of recombinant factor VIIa. *J Thromb Haemost.* 2003; 1:1138-1139.
11. Lisman T, Adelmeijer J, Nieuwenhuis HK, de Groot PG. Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting factor Xa, but not by those inhibiting thrombin or tissue factor. *Blood Coag Fibrinol.* 2003; 14: 557-562.
12. Lisman T, de Groot PG, Lambert T, Røjkjær R, Persson E. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. *J Thromb Haemost.* 2003; 1: 2175-2178.
13. Lisman T, Bijsterveld NR, Adelmeijer J, Meijers JCM, Levi M, Nieuwenhuis HK, de Groot PG. Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux. *J Thromb Haemost.* 2003; 1: 2368-2373.
14. Lisman T, Adelmeijer J, Heijnen HFG, de Groot PG. Recombinant factor VIIa restores aggregation of alpha IIb beta 3 deficient platelets via tissue factor-independent fibrin generation. *Blood.* 2004; 103: 1720-1727.

15. Schutgens REG, Esseboom EU, Snijder RJ, Haas FJLM, Verzijlbergen F, Nieuwenhuis HK, Lisman T, Biesma DH. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism. *J Lab Clin Med.* 2004;144(2):100-7.
16. Beerepoot LV, Mehra N, Linschoten F, Jorna AS, Lisman T, Verheul HMW, Voest EE. Circulating endothelial cells in cancer patients do not express tissue factor. *Cancer Lett.* 2004; 213(2):241-8.
17. Lisman T, Adelmeijer J, Cauwenberghs S, van Pampus ECM, Heemskerk J, de Groot PG. Recombinant factor VIIa enhances platelet adhesion and activation under flow at normal and reduced platelet count. *J. Thromb. Haemost.* 2005; 3: 742-751.
18. Lisman T, de Groot PG, Meijers JCM, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. *Blood* 2005; 105: 1102-1105.
19. Lisman T, Weeterings C, de Groot PG. Platelet aggregation: involvement of thrombin and fibrin(ogen). *Frontiers in biosciences*, Front Biosci. 2005;10:2504-17.
20. de Groot PG, Lutters BHC, Derksen RWHM, Lisman T, Meijers JCM, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. *J Thromb Haemost*; 3: 1993-1997.
21. Sundaram V, Al-Osaimi AMS, Lewis JJ, Lisman T, Caldwell SH. Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related? *Dig Dis Sci.*, 2006, 51: 1203-1205.
22. van Marion AMW, Auwerda JJA, Minnema MC, van Oosterom R, Adelmeijer J, de Groot PG, Leebeek FWG, Sonneveld P, Lokhorst HM, Lisman T. Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis. *Thromb. Haemost* 2005;94: 1341-1343.
23. Liu ZH, Wei R, Wu YP, Lisman T, Wang ZX, Han JJ, Ren DL, Chen B, Zhu Z, Zhang Y, Cui X, Hu HT, de Groot PG, Xu WB. Elevated plasma tissue-type plasminogen activator (t-PA) and soluble thrombomodulin in patients suffering from severe acute respiratory syndrome (SARS) as a possible index for prognosis and treatment strategy. *Biomed. Environ. Sci.* 2005;18: 260-264.
24. Weeterings C, Adelmeijer J, Myles T, de Groot PG, Lisman T. Glycoprotein Ib(alpha)-mediated platelet adhesion and aggregation to immobilized thrombin under conditions of flow. *Arterioscler Thromb Vasc Biol.* 2006;26:670-675.
25. Heyligers J, Verhagen HJM, Rotmans JI, Weeterings C, de Groot PG, Moll FL, Lisman T. Heparin immobilization reduces thrombogenicity of small-caliber ePTFE grafts. *J Vasc Surg*, 2006;43: 587-591.
26. Martini CH, Brandts A, de Bruijne ELE, van Hylckama Vlieg A, Leebeek FWG, Lisman T, Rosendaal FR. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. *Br. J. Haemat.* 2006; 134: 92-94.
27. Lisman T, Bongers T, Adelmeijer J, Janssen HLA, de Maat MPM, de Groot PG, Leebeek FWG. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. *Hepatology*, 2006;44:53-61.
28. Lebbink RJ, de Ruiter T, Adelmeijer J, Brenkman AB, van Helvoort JM, Koch M, Farndale RW, Lisman T, Sonnenberg A, Lenting PJ, Meyaard L. Collagens are functional, high-affinity ligands for the inhibitory immune receptor LAIR-1. *J. Exp. Med*, 2006;103:1419-1425.
29. Caldwell SH, Hoffman M, Lisman T, Macik BG, Northup PG, Reddy KR, Tripodi A, Sanyal AJ. Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current management. *Hepatology* 2006; 44:1039-46.
30. Lisman T, Caldwell SH, Porte RJ, Leebeek FWG. Hemostasis in chronic liver disease: consequences of abnormal hemostasis tests for clinical practice. *J Thromb Haemost* 2006; 4: 2062-2063.
31. Lisman T, Caldwell SH, Leebeek FWG, Porte RJ. Hemostasis in chronic liver disease: is chronic liver disease associated with a bleeding diathesis? *J Thromb Haemost* 2006; 4: 2059-2060.
32. Lisman T, Porte RJ, Leebeek FWG, Caldwell SH. Hemostasis in chronic liver disease: methodological issues with coagulation testing in patients with liver disease. *J Thromb Haemost* 2006; 4: 2061-2062.
33. Lisman T, Adelmeijer J, Janssen HLA, de Groot PG, Leebeek FWG. No evidence for an intrinsic platelet defect in patients with liver cirrhosis – studies under flow conditions. *J Thromb Haemost* 2006; 4: 2070-2072.
34. Wu YP, Wei R, Liu ZH, Chen B, Lisman T, Ren DL, Han JJ, Xia ZL, Zhang FS, Xu WB, Preissner KT, de Groot PG. Analysis of thrombotic factors in severe acute respiratory syndrome (SARS) patients. *Thromb Haemost* 2006;96: 100-101.
35. Lisman T, Raynal N, Groeneveld D, Maddox B, Peachey A, Huizinga EG, de Groot PG, Farndale RW. Identification of the von Willebrand factor binding site in collagen using triple helical peptides. *Blood* 2006; 108: 3753-6.
36. Pennings MTT, Derksen RHWM, van Lummel M, Adelmeijer J, VanHoorelbeke K, Urbanus RT, Lisman T, de Groot PG. Platelet adhesion to dimeric beta2-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ib(alpha) and APOER2'. *J Thromb Haemost.* 2006; 5: 369-377.

37. van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, Goudemand J, Fressinaud E, van den Berg M, de Groot PG, Lenting PJ. Variations in glycosylation of von Willebrand factor with O-linked sialylated T-antigen are associated with its plasma levels. *Blood* 2007; 109: 2430-2437.
38. Lisman T, Porte RJ. Anti-platelet medication after liver transplantation: does it effect outcome? *Liver transplantation* 2007; 13: 644-646.
39. Meltzer ME, Doggen CJM, de Groot PG, Rosendaal FR, Lisman T. Fibrinolysis and the risk of venous and arterial thrombosis. *Curr Opin Haematol.* 2007; 14: 242-248.
40. Lisman T, Leebeek FWG. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. *Dig. Surg.* 2007, 24(4):250-8.
41. Lisman T, Farndale RW, de Groot PG. A mechanism to safeguard platelet adhesion under high-shear flow: von Willebrand factor-glycoprotein Ib and integrin alpha2beta1-collagen interactions make complementary, collagen-type-specific contributions to adhesion: a rebuttal. *J Thromb Hemost.* 2007; 6: 1338-1339.
42. Korporaal SJ, Van Eck M, Adelmeijer J, IJsseldijk M, Out R, Lisman T, Lenting PJ, Van Berkel TJ, Akkerman JW. Platelet Activation by Oxidized Low Density Lipoprotein Is Mediated by Cd36 and Scavenger Receptor-A. *Arterioscler Thromb Vasc Biol.* 2007, 27:2476-83.
43. Xiao Min Zhao , Ya Ping Wu , Hong Xin Cai , Ran Wei , Lisman T, Ji Ju Han , Zuo Li Xia , de Groot PG. The influence of the pulsatility of the blood flow on the extent of platelet adhesion. *Thromb Res.* 2008, 121:821-825.
44. Heyligers JMM, Lisman T, Verhagen HJM, Weeterings C, de Groot PG, Moll FL. A heparin-bonded vascular graft generates no systemic effect on markers of haemostasis activation or detectable HIT-inducing antibodies in humans. *J Vasc Surg* 2008, 47: 324-329.
45. Warnaar N, Lisman T, Porte RJ. The two tales of coagulation in liver transplantation. *Curr. Opin. Organ Transp.* 2008, 13; 298-303.
46. Pereboom ITA, Lisman T, Porte RJ. Platelets in liver transplantation – friend or foe? *Liver Transplantation* 2008, 14: 923-931.
47. Meltzer ME, Lisman T, Doggen CMJ, de Groot PG, Rosendaal FR. Synergistic Effects of Hypofibrinolysis and Genetic and Acquired Risk Factors on the Risk of a First Venous Thrombosis. *Plos Med* 2008, 2008 May 6;5(5):e97.
48. van Marion AM, Auwerda JJ, Lisman T, Sonneveld P, de Maat MP, Lokhorst HM, Leebeek FW. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens. *Leuk Res.* 2008, 2008 Jul;32(7):1078-84.
49. Weeterings C, Lisman T, de Groot PG. Tissue factor-independent effects of recombinant factor VIIa on hemostasis. *Semin Hematol* 2008; 45(suppl 1):S12-S15.
50. Lisman T, van Leeuwen Y, Adelmeijer J, Pereboom ITA, Haagsma EB, van den Berg AP, Porte RJ. Inter-laboratory variability in assessment of the model of end-stage liver disease (MELD) score. *Liver Int* 2008, 28:1344-51.
51. Farndale RW, Lisman T, Bihan D, Hamaia S, Smerling CS, Pugh N, Konitsiotis A, Leitinger B, de Groot PG, Jarvis GE, Raynal N. Cell-collagen interactions: the use of peptide Toolkits to investigate collagen-receptor interactions. *Biochem Soc Trans.* 2008 Apr;36(Pt 2):241-50.
52. Wu YP, Zhao XM, Pan SD, Guo DA, Wei R, Han JJ, Kainoh M, Xia ZL, de Groot PG, Lisman T. Salvianolic Acid B inhibits platelet adhesion under conditions of flow by a mechanism involving the collagen receptor $\alpha 2\beta 1$. *Thromb. Res* 2008, 123:298-305.
53. van Stralen K, Doggen CJ, Bezemer I, Pomp E, Lisman T, Rosendaal FR.. Mechanisms of the factor Vleiden paradox. *Atheroscl. Thromb. Vasc. Biol*, 2008, 28:1872-7.
54. Weeterings C, Adelmeijer J, de Groot PG, Lisman T. Glycoprotein Ib[alpha] contributes to tissue factor-independent thrombin generation by recombinant factor VIIa on the activated platelet surface. *Blood* 2008, 112:3227-33.
55. Lisman T, Porte RJ. Hepatic artery thrombosis after liver transplantation: more than just a surgical complication? *Transpl. Int.* 2009, 22: 162-163.
56. Pereboom IT, de Boer MT, Haagsma EB, Hendriks HG, Lisman T, Porte RJ. Platelet transfusion during liver transplantation is associated with increased postoperative mortality due to acute lung injury. *Anesth Analg.* 2009;108:1083-91.
57. Wichers IM, Tanck MWT, Meijers JCM, Lisman T, Reitsma PH, Rosendaal FR, Buller HR, Middeldorp S. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia. *Thromb Haemost.* 2009;101465-70.
58. Pereboom ITA, Adelmeijer J, van Leeuwen Y, Hendriks HGD, Porte RJ, Lisman T. No evidence for systemic platelet activation during and after orthotopic liver transplantation. *Liver Transpl.* 2009;15:956-62.

59. Meltzer ME, Doggen CJM, de Groot PG, Rosendaal FR, Lisman T. Reduced plasma fibrinolytic potential and the risk of a first myocardial infarction in men. *Br J Haematol*. 2009;145:121-7.
60. Guimaraes A, de Bruijne E, Lisman T, Dippel D, Deckers J, Poldermans D, Rijken D, Leebeek F. Hypofibrinolysis as risk factor for arterial thrombosis. *Br J Haematol*. 2009;145:115-20.
61. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. *Semin Thromb Hemost*. 2009;35:468-77.
62. Meltzer ME, Doggen CJ, de Groot PG, Meijers JC, Rosendaal FR, Lisman T. Decreased TAFI levels are associated with an increased risk of a first myocardial infarction in men. *Haematologica*. 2009;94:811-8.
63. Pereboom ITA, Adelmeijer J, van Leeuwen Y, Hendriks HGD, Porte RJ, Lisman T. Development of a severe von Willebrand Factor/ADAMTS13 dysbalance during orthotopic liver transplantation. *Am J Transplant*. 2009;9:1189-96.
64. Ramaker AJ, Meyer P, van der Meer J, Struys MM, Lisman T, van Oeveren W, Hendriks HG. Effects of acidosis, alkalosis, hyperthermia and hypothermia on haemostasis: results of point of care testing with the thromboelastography analyser. *Blood Coagul Fibrinolysis*. 2009;20:436-9.
65. Yang H, Plosch T, Lisman T, Gouw AS, Porte RJ, Verkade HJ, Hulscher JB. Title: Inflammation mediated down-regulation of hepatobiliary transporters contributes to intrahepatic cholestasis and liver damage in murine biliary atresia. *Pediatr Res*. 2009; 66:380-5.
66. de Haas CJ, Weeterings C, Vughs MM, de Groot PG, van Strijp JA, Lisman T. Staphylococcal superantigen-like 5 activates platelets and supports platelet adhesion under flow conditions, which involves glycoprotein Iba and alphaIIb beta3. *J Thromb Haemost*. 2009, 7:1867-74.
67. Alkozai E, Lisman T, Porte RJ. Bleeding in liver surgery: prevention and treatment. *Clin Liver Dis*. 2009, 13: 145-154.
68. Hugenholtz GCM, Porte RJ, Lisman T. The platelet and platelet function testing in liver disease. *Clin Liver Dis*. 2009, 13: 11-20.
69. Senzolo M, Sartori MT, Lisman T. Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? *HPB (Oxford)*. 2009;11:459-64.
70. Westerkamp A, Lisman T, Porte RJ. How to minimize blood loss during liver surgery in patients with cirrhosis? *HPB (Oxford)*. 2009;11:453-8.
71. van der Werf J, Porte RJ, Lisman T. Hemostasis in liver disease. *Acta Gastroent Belgica* 2009, 72:433-40.
72. Lisman T. Platelet binding to factor XI – Glycoprotein Iba has an accomplice. *Atheroscl. Thromb. Vasc Biol* 2009, 29:1409-10.
73. Lisman T, Bakhtiari K, Pereboom IT, Hendriks HGD, Meijers JC, Porte RJ. Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests. *J Hepatol* 2010, 52:355-61.
74. Meltzer ME, Bol-van Kleef L, Rosendaal FR, Lisman T, Cannegieter SC. Hypofibrinolysis as risk factor for recurrent venous thrombosis; results of the LETS follow up study. *J Thromb Haemost* 2010, 8:605-7.
75. Lisman T. Activation of coagulation by living donor kidney transplants early after reperfusion. *Am J Transpl*. 2010 Feb;10:434.
76. Alkozai E, Nijsten MW, de Jong KP, de Boer MT, Peeters PMJG, Slooff MJ, Porte RJ, Lisman T. Immediate postoperative low platelet count is associated with delayed liver function recovery after partial liver resection. *Ann Surg* 2010;251:300-6.
77. Pereboom IT, de Boer MT, Haagsma EB, van der Heide F, Porcelijn L, Lisman T, Porte RJ. Transmission of idiopathic thrombocytopenic purpura during orthotopic liver transplantation. *Transpl Int*. 2010 Feb;23:236-8.
78. Porte RJ, Lisman T, Tripodi A, Caldwell SH, Trotter JF. The international normalized ratio (INR) in the MELD score: problems and solution. *Am J Transpl* 2010, 10:1349-53.
79. Lisman T, Porte RJ. Activation and regulation of hemostasis in acute liver failure and acute pancreatitis. *Semin Thromb Hemost* 2010, 36:437-43.
80. Lisman T, Caldwell SH, Burroughs AK, Northup PG, Senzolo M, Stravitz RT, Tripodi A, Trotter JF, Valla DC, Porte RJ. Hemostasis and Thrombosis in patients with liver disease: the ups and downs. *J Hepatol* 2010, 53:362-71.
81. Lisman T, Porte RJ. The role of platelets in liver inflammation and regeneration. *Semin Thromb Hemost* 2010, 36:170-4.
82. Tripodi A, Baglin T, Robert A, Kitchen S, Lisman T, Trotter JF. Reporting prothrombin time results as international normalised ratio for patients with chronic liver disease. *J Thromb Haemost* 2010, 8:1410-2.

83. Bongers TN, Emonts M, de Maat MP, de Groot R, Lisman T, Hazelzet JA, Leebeek FW. Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. *Thromb Haemost*. 2010, 103: 1181-7.
84. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Plasma levels of fibrinolytic proteins and the risk of myocardial infarction in men. *Blood* 2010, 116:529-36.
85. Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Sessie S, Doggen CJ, Rosendaal FR. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1. *Blood* 2010, 116:113-21.
86. Ruitenbeek K, Meijers JC, Adelmeijer J, Hendriks HGD, Porte RJ, Lisman T. Intact thrombomodulin-mediated regulation of fibrinolysis during and after liver transplantation, despite a profoundly defective thrombomodulin-mediated regulation of coagulation. *J Thromb Haemost* 2010, 8:1646-9.
87. Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. *Blood* 2010, 116:878-85.
88. Lisman T, Caldwell SH, Porte RJ. Anemia as a potential contributor to bleeding in patients with liver disease - neglected but not forgotten. *J Hepatol* 2011, 54: 594-595
89. op den Dries S, Buis CI, Adelmeijer J, van der Jagt EJ, Haagsma EB, Lisman T, Porte RJ. Combination of primary sclerosing cholangitis and CCR5-Δ32 in recipients is strongly associated with development of nonanastomotic biliary strictures after liver transplantation. *Liver Int*. 2011 Sep;31(8):1102-9.
90. Lisman T, Platto M, Meijers, JCM, Haagsma EB, Colledan M, Porte RJ. The hemostatic status of pediatric recipients of adult liver grafts suggests that plasma levels of hemostatic proteins are not regulated by the liver. *Blood* 2011, 117:2070-2.
91. Lisman T, Porte RJ. Towards a rational use of low molecular weight heparin in patients with cirrhosis. *Liver Int*. 2011, 31: 1063.
92. Lisman T, Porte RJ. Recombinant factor VIIa to treat severe bleeding in patients with liver disease: pitfalls and possibilities. *J Hepatol*. 2011 Oct;55(4):950-1.
93. Meltzer ME, Hasstedt SJ, Vossen CY, Callas PW, Doggen CJM, de Groot PG, Rosendaal FR, Lisman T, Bovill EG. Genome scan of clot lysis time and its association with thrombosis in a protein C deficient kindred. *J Thromb Haemost* 2011, 9:1383-90.
94. Uitte de Willige S, Miedzak M, Carter AM, Lisman T, Rosendaal FR, Grant PJ, Philippou H, Ariëns RA. Proteolytic and genetic variation of the alpha2-antiplasmin C-terminus in myocardial infarction. *Blood* 2011 117:6694-701.
95. op den Dries S, Sutton ME, Lisman T, Porte RJ. Protection of Bile Ducts in Liver Transplantation: Looking Beyond Ischemia. *Transplantation* 2011 92:373-9.
96. Pereboom ITA, Adelmeijer J, van der Steege G, van den Berg AP, Lisman T, Porte RJ. Prothrombotic gene polymorphisms: possible contributors to hepatic artery thrombosis after orthotopic liver transplantation. *Transplantation*. 2011 Sep 15;92(5):587-93.
97. Lisman T, Leuvenink HG, Porte RJ, Ploeg RJ. Activation of hemostasis in brain dead organ donors. *J Thromb Haemost*. 2011 Oct;9(10):1959-65.
98. Stravitz RT, Lisman T, Luketic VA, Sterling RK, Puri P, Fuchs M, Ibrahim A, Lee WM, Sanyal AJ. Minimal Effects of Acute Liver Injury/Acute Liver Failure on Hemostasis as Assessed by Thromboelastography. *J Hepatol*. 2012 Jan;56(1):129-36.
99. Boonstra EA, Adelmeijer J, Verkade HJ, de Boer MT, Porte RJ, Lisman T. Fibrinolytic proteins in human bile accelerate lysis of plasma clots and induce breakdown of fibrin sealants. *Ann Surg* 2012 Aug;256(2):306-12.
100. Lisman T, Porte RJ. Platelet function in patients with cirrhosis. *J Hepatol*. 2012 Apr;56(4):993-4.
101. Siegerink B, Meltzer ME, de Groot PG, Algra A, Lisman T, Rosendaal FR. Clot lysis time and the risk of myocardial infarction and ischaemic stroke in young women; results from the RATIO case-control study. *Br J Haematol*. 2012 Jan;156(2):252-8.
102. Lisman T, Porte RJ. Pitfalls in assessing platelet activation status in patients with liver disease. *Liver Int* 2012 Jul;32(6):1027.
103. Sutton ME, op den Dries S, Koster MH, Lisman T, Gouw ASH, Porte RJ. Regeneration of human extrahepatic biliary epithelium: the peribiliary glands as progenitor cell compartment. *Liver Int*. 2012 Apr;32(4):554-9.
104. Gallandat Huet RC, Cernak V, de Vries AJ, Lisman T. Bivalirudin is inferior to heparin in preservation of intraoperative autologous blood. *Thromb Res* 2012, 130(2):163-5.
105. Gallandat Huet RC, Cernak V, de Vries AJ, Lisman T. Platelet function in stored heparinised autologous blood is not superior to in patient platelet function during routine cardiopulmonary bypass. *PLoS One*. 2012;7(3):e33686.
106. Stellingwerf M, Brandsma A, Lisman T, Porte RJ. Prohemostatic interventions in liver surgery. *Semin. Thromb. Haemost*. 2012, 38(3):244-9.

107. Lisman T, Meltzer ME, Cannegieter SC, Rosendaal FR. Plasma levels of Midkine (neurite growth-promoting factor 2) are not associated with plasma fibrinolytic potential or risk of venous thrombosis. *J Thromb Haemost* 2012, 38(3):244-9.
108. de Boer MT, Boonstra EA, Lisman T, Porte RJ. Role of fibrin sealants in liver surgery. *Dig Surg*. 2012;29(1):54-61
109. Lisman T, Bakthiari K, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT. Intact thrombin generation and decreased fibrinolytic capacity in patients with acute liver injury or acute liver failure. *J. Thromb. Haemost.* 2012, 10(7):1312-9.
110. Kele PG, de Boer MT, van der Jagt EJ, Lisman T, Porte RJ. Early hepatic regeneration and completeness of regeneration at six months after partial hepatectomy. *Br. J. Surg.* 2012, 99(8):1113-9.
111. Lisman T, Pittau G, Leite FJT, de Boer MT, Meijer K, Kluin-Nelemans HC, Huls G, te Boome LCJ, Kuball J, Nowak G, Fan ST, Azoulay D, Porte RJ. The circulating platelet count is not dictated by the liver, but may be determined in part by the bone marrow – analyses from human liver and stem cell transplantations. *J. Thromb. Haemost.* 2012, 10(8):1624-30.
112. Bos EM, Snijder PM, Jekel H, Weij M, Leemans JC, van Dijk MC, Hillebrands JL, Lisman T, van Goor H, Leuvenink HG. Beneficial effects of gaseous hydrogen sulfide in hepatic ischemia/reperfusion injury. *Transpl. Int.* 2012, 25(8):897-908.
113. Lisman T, Porte RJ. Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. *N Engl J Med.* 2012;367(21):2055-6.
114. Kele PG, van der Jagt EJ, Gouw AS, Lisman T, Porte RJ, de Boer MT. The impact of hepatic steatosis on liver regeneration after partial hepatectomy. *Liver Int.* 2013 Mar;33(3):469-75.
115. Op den Dries S, Karimian N, Sutton ME, Westerkamp AC, Nijsten MW, Gouw AS, Wiersema-Buist J, Lisman T, Leuvenink HG, Porte RJ. Ex vivo Normothermic Machine Perfusion and Viability Testing of Discarded Human Donor Livers. *Am J Transplant.* 2013 May;13(5):1327-35.
116. Hugenholtz GC, Adelmeijer J, Meijers JC, Porte RJ, Stravitz RT, Lisman T. An unbalance between von Willebrand factor and ADAMTS13 in acute liver failure: Implications for hemostasis and clinical outcome. *Hepatology.* 2013 Aug;58(2):752-61.
117. Hugenholtz GC, Meijers JC, Adelmeijer J, Porte RJ, Lisman T. TAFI deficiency promotes liver damage in murine models of liver failure through defective down-regulation of hepatic inflammation. *Thromb Haemost.* 2013 May 2;109(5):948-55.
118. Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis - Possibilities and caveats. *J Hepatol.* 2013 Aug;59(2):358-66.
119. Arshad F, Lisman T, Porte RJ. Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient. *Liver Int.* 2013 Jul;33(6):820-7.
120. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, Porte RJ, Lisman T. Decreased tissue factor pathway inhibitor (TFPI)-dependent anticoagulant capacity in patients with cirrhosis who have decreased protein S but normal TFPI plasma levels. *Br J Haematol.* 2013 Sep;162(6):819-26.
121. Adelmeijer J, Porte RJ, Lisman T. In vitro effects of proteases in human pancreatic juice on stability of liquid and carrier-bound fibrin sealants. *Br J Surg.* 2013 Oct;100(11):1498-504.
122. Arshad F, Ickx B, van Beem RT, Polak W, Grüne F, Nevens F, Ilmakunnas M, Koivusalo AM, Iso-niemi H, Strengers PF, Groen H, Hendriks HG, Lisman T, Pirenne J, Porte RJ. Prothrombin complex concentrate in the reduction of blood loss during orthotopic liver transplantation: PROTON-trial. *BMC Surg.* 2013 Jul 1;13:22.
123. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, Porte RJ, Lisman T. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. *British Journal of Haematology*, 2013, 163(5):666-73.
124. Hyseni A, Kemperman H, de Lange DW, de Groot PG, Linssen M, Kesecioglu J, Lisman T, Roest M. Increased mortality in systemic inflammatory response syndrome patients with high levels of coagulation factor VIIa. *J Thromb Haemost.* 2013 Dec;11(12):2111-7
125. Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. *Liver Int.* 2014 Jan;34(1):26-32
126. Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, Porte RJ, Lisman T. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. *PLoS ONE* 2014 9(2): e88390.
127. Sutton ME, Bense RD, Lisman T, van der Jagt EJ, van den Berg AP, Porte RJ. Duct-to-duct reconstruction in liver transplantation for PSC is associated with less biliary complications, compared with hepatico-jejunostomy. *Liver Transpl.* 2014 Apr;20(4):457-63.

128. Op den Dries S, Westerkamp A, Karimian N, Gouw ASH, Markmann JF, [Lisman T](#), Yeh H, Uygun K, Martins P, Porte RJ. Injury to Peribiliary Glands and Vascular Plexus before Liver Transplantation Predicts Formation of Non-anastomotic Biliary Strictures. *J Hepatol.* 2014 Jun;60(6):1172-9.
129. Schut AM, Hyseni A, Adelmeijer J, Meijers JC, de Groot PG, [Lisman T](#). Sustained prohemostatic activity of recombinant factor VIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylactic regimen in humans. *Thromb Haemost.* 2014 Aug;112(2):304-10.
130. Weeder P, Porte RJ, [Lisman T](#). Hemostasis in liver disease: implications of new concepts for peri-operative management *Transfusion Medicine Reviews.* *Transfus Med Rev.* 2014 Jul;28(3):107-13.
131. Op den Dries S, Sutton ME, Karimian N, de Boer MT, Wiersema-Buist J, Gouw AS, Leuvenink HG, [Lisman T](#), Porte RJ. Hypothermic oxygenated machine perfusion prevents arteriolonecrosis of the peribiliary plexus in pig livers donated after circulatory death. *PLoS One.* 2014 Feb 14;9(2):e88521
132. Arshad F, Adelmeijer J, Blokzijl H, van den Berg A, Porte R, [Lisman T](#). Abnormal hemostatic function one year after orthotopic liver transplantation can be fully attributed to endothelial cell activation *F1000Research* 2014, 3:103
133. Alkozai EM, [Lisman T](#), Porte RJ, Nijsten MW. Early elevated serum gamma glutamyl transpeptidase after liver transplantation is associated with better survival. *F1000Res.* 2014 Apr 3;3:85
134. Sutton ME, op den Dries S, Karimian N, Weeder PD, de Boer MT, Wiersema-Buist J, Gouw AS, Leuvenink HG, [Lisman T](#), Porte RJ. Criteria for viability assessment of discarded human donor livers during ex vivo normothermic machine perfusion. *PLoS One.* 2014 Nov 4;9(11):e110642.
135. [Lisman T](#). Low molecular weight heparin in management and prevention of portal vein thrombosis. *Thromb Res.* 2014 Oct;134(4):761-2.
136. Potze W, Porte RJ, [Lisman T](#). Management of coagulation abnormalities in liver disease. *Expert Rev Gastroenterol Hepatol.* 2015 Jan;9(1):103-14.
137. Wiewel-Verschueren S, Knol HM, [Lisman T](#), Bogchelman DH, Kluin-Nelemans JC, van der Zee AG, Mulder AB, Meijer K. No increased systemic fibrinolysis in women with heavy menstrual bleeding. *J Thromb Haemost.* 2014 Sep;12(9):1488-93.
138. Potze W, Adelmeijer J, [Lisman T](#). Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. *Hepatology* 2015, 61(4):1435-6.
139. Potze W, [Lisman T](#). Issues with monitoring of unfractionated heparin in cirrhosis. *Ther Drug Monit.* 2015;37(2):279-80.
140. Potze W, Alkozai EM, Adelmeijer J, Porte RJ, [Lisman T](#). Hypercoagulability following major partial liver resection - detected by thrombomodulin-modified thrombin generation testing. *Aliment Pharmacol Ther.* 2015 Jan;41(2):189-98.
141. Groeneveld D, Porte RJ, [Lisman T](#). Thrombomodulin-modified thrombin generation testing detects a hypercoagulable state in patients with cirrhosis regardless of the exact experimental conditions. *Thromb Res.* 2014;134(3):753-6.
142. Alkozai EM, Porte RJ, Adelmeijer J, Zanetto A, Simioni P, Senzolo M, [Lisman T](#). Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma. *Platelets* 2015;26(6):577-82.
143. [Lisman T](#). Platelets and fibrin in progression of liver disease: friends or foes? *J Thromb Haemost.* 2015 Jan;13(1):54-6
144. Alkozai EM, Porte RJ, Adelmeijer J, Zanetto A, Simioni P, Senzolo M, [Lisman T](#). No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma. *Thromb Res.* 2015 Feb;135(2):292-7.
145. Hugenholtz GC, Northup PG, Porte RJ, [Lisman T](#). Is there a rationale for treatment of chronic liver disease with antithrombotic therapy? *Blood Rev* 2015;29(2):127-36.
146. Schut AM, Venemans-Jellema A, Meijers JC, Middeldorp S, de Groot PG, Rosendaal FR, Roest M, [Lisman T](#), Cannegieter SC. Coagulation activation during air travel is not initiated via the extrinsic pathway. *Br J Haematol* 2015;169(6):903-5.
147. Arshad F, Stoof SC, Leebeek FW, Ruitenbeek K, Adelmeijer J, Blokzijl H, van den Berg AP, Porte RJ, Kruip MJ, [Lisman T](#). Infusion of DDAVP does not improve primary hemostasis in patients with cirrhosis. *Liver Int* 2015;35(7):1809-15.
148. Alkozai EM, van Faassen M, Kema IP, Porte RJ, [Lisman T](#). Evidence against a role of serotonin in liver regeneration in humans. *Hepatology* 2015;62(3):983.
149. [Lisman T](#), de Groot PG. The role of cell surfaces and cellular receptors in the mode of action of recombinant factor VIIa. *Blood Rev.* 2015;29(4):223-9.
150. Hugenholtz G.C.G., [Lisman T](#). Regulation of VWF reactivity by plasmin: a backup mechanism against thrombosis in pathologies beyond TTP? *Circulation.* 2015 Jan 13;131(2):e18.
151. Ruitenbeek K, Hugenholtz GCG, Adelmeijer J, Pereboom ITA, Meijers JCM, Porte RJ, Erasmus ME, [Lisman T](#). Development of a hypercoagulable status in patients undergoing off-pump lung transplanta-

- tion despite prolonged conventional coagulation tests. *Am J Respir Crit Care Med.* 2015 Jan 15;191(2):230-3
152. [Lisman T](#), Stravitz RT. Rebalanced hemostasis in patients with acute liver failure. *Semin Thromb Hemost* 2015;41(5):468-73.
 153. Hugenholtz GCG, Ruitenbeek K, Adelmeijer J, Pereboom ITA, Meijers JCM, vd Bij W, Porte RJ, Erasmus ME, [Lisman T](#). Development of a Hyperactive Primary Hemostatic System During Off-Pump Lung Transplantation Resulting From an Unbalance Between Von Willebrand Factor and Its Cleaving Protease ADAMTS13. *Am J Trans* 2015,15(7):1958-66.
 154. Potze W, Adelmeijer J, Porte RJ, [Lisman T](#). Preserved clot formation detected by the Thrombodynamics analyzer in patients with cirrhosis. *Thromb Res.* 2015;135(5):1012-6.
 155. Schut AM, Meijers JCM, Lisman-van Leeuwen Y, van Montfoort ML, Roest M, de Groot PG, Urbanus RT, Coppens M, [Lisman T](#). Decreased plasma levels of activated factor VII in patients with deep vein thrombosis. *J Thromb. Haemost* 2015;13(7):1320-4.
 156. Karimian N, Matton AP, Westerkamp AC, Burlage LC, Op den Dries S, Leuvenink HG, [Lisman T](#), Uygun K, Markmann JF, Porte RJ. Ex Situ Normothermic Machine Perfusion of Donor Livers. *J Vis Exp.* 2015 May 26;(99).
 157. Burlage LC, Karangwa SA, [Lisman T](#), Martins PN, Porte RJ. Thrombolytic protocol minimizes ischemic-type biliary complications in liver transplantation from donation after circulatory death donors. *Liver Transpl.* 2015 Sep;21(9):1231-2
 158. Kirschbaum M, Karimian G, Adelmeijer J, Giepmans BN, Porte RJ, [Lisman T](#). Horizontal RNA transfer mediates platelet-induced hepatocyte proliferation. *Blood.* 2015;126(6):798-806.
 159. [Lisman T](#), Kirschbaum M, Porte RJ. The role of platelets in liver regeneration - what don't we know? *J Hepatol.* 2015;63(6):1537-8.
 160. [Lisman T](#), Kwaan HC. Hemostatic Dysfunction in Liver Diseases. *Semin Thromb Hemost.* 2015 Jul;41(5):445-6.
 161. Westerkamp AC, Mahboub P, Meyer SL, Hottenrot M, Ottens PJ, Wiersema-Buist J, Gouw AS, [Lisman T](#), Leuvenink HG, Porte RJ. End-Ischemic Machine Perfusion Reduces Bile Duct Injury In Donation After Circulatory Death Rat Donor Livers. *Liver Transpl.* 2015;21(10):1300-11.
 162. Intagliata NM, Caldwell SH, Porte RJ, [Lisman T](#). Prediction of bleeding in cirrhosis patients: Is the forecast any clearer? *Hepatology.* 2015 Dec 24. doi: 10.1002/hep.28426.
 163. Karimian G, Kirschbaum M, Veldhuis ZJ, Bomfati F, Porte RJ, [Lisman T](#). Vitamin E Attenuates the Progression of Non-Alcoholic Fatty Liver Disease Caused by Partial Hepatectomy in Mice. *PLoS One.* 2015 Nov 24;10(11):e0143121..
 164. Stravitz RT, Ellerbe C, Durkalski V, Reuben A, [Lisman T](#), Lee WM; Acute Liver Failure Study Group. Thrombocytopenia Is Associated With Multi-organ System Failure in Patients With Acute Liver Failure. *Clin Gastroenterol Hepatol.* 2016; 14(4):613-620.
 165. Groeneveld DJ, Adelmeijer J, Hugenholtz GC, Ariëns RA, Porte RJ, [Lisman T](#). Ex vivo addition of fibrinogen concentrate improves fibrin network structure in plasma samples taken during liver transplantation. *J Thromb Haemost.* 2016; 13(12):2192-201.
 166. Westerkamp AC, Pully VV, Karimian G, Bomfati F, Veldhuis ZJ, Wiersema-Buist J, Hendriks BH, [Lisman T](#), Porte RJ. Diffuse reflectance spectroscopy accurately quantifies various degrees of liver steatosis in murine models of fatty liver disease. *J Transl Med.* 2015 Sep 21;13(1):309.
 167. Westerkamp AC, Karimian N, Matton AP, Mahboub P, van Rijn R, Wiersema-Buist J, de Boer MT, Leuvenink HG, Gouw AS, [Lisman T](#), Porte RJ. Oxygenated Hypothermic Machine Perfusion After Static Cold Storage Improves Hepatobiliary Function of Extended Criteria Donor Livers. *Transplantation* 2016; 100(4):825-35.
 168. Hugenholtz GC, Macrae F, Adelmeijer J, Dulfer S, Porte RJ, [Lisman T](#), Ariëns RA. Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen. *J Thromb Haemost.* 2016;14(5):1054-66.
 169. [Lisman T](#), Porte RJ. Plasma molecules predicting liver dysfunction following partial hepatectomy are not only derived from platelet α -granules. *Hepatology* 2016, 64(3):991-2.
 170. [Lisman T](#), Ariëns RAS. Alterations in fibrin structure in patients with liver diseases. *Semin Thromb Haemost* 2016;42(4):389-96.
 171. [Lisman T](#), de Moerloose P. The Role of Fibrinogen and Factor XIII in Hemostasis, and the Identification and Treatment of Associated Disorders. *Semin Thromb Haemost* 2016;42(4):331-2.
 172. Op den Dries S, Karimian N, Westerkamp AC, Sutton ME, Kuipers M, Wiersema-Buist J, Ottens PJ, Kuipers J, Giepmans BN, Leuvenink HG, [Lisman T](#), Porte RJ. Normothermic machine perfusion reduces bile duct injury and improves biliary epithelial function in rat donor livers. *Liver Transpl* 2016; 22(7):994-1005

173. Groeneveld DJ, Alkozai EM, Adelmeijer J, Porte RJ, Lisman T. Balance between von Willebrand factor and ADAMTS13 following major partial hepatectomy. *Br J Surg* 2016, in press.
174. Kleiss SF, Adelmeijer J, Meijers JC, Porte RJ, Lisman T. A sustained decrease in plasma fibrinolytic potential following partial liver resection or pancreas resection. *Thromb Res* 2016;140:36-40.
175. Schut AM, Kirschbaum M, Adelmeijer J, de Groot PG, Lisman T. In vitro uptake of recombinant factor VIIa by megakaryocytes with subsequent production of platelets containing functionally active drug. *Br J. Haematol.* 2016, in press.
176. Lisman T. Fibrin fixes fibrosis. *Blood* 2016;127(22):2662-4.
177. Lisman T. Assessing in vivo platelet activation in patients with liver diseases. *J Thromb Thrombolysis* 2016, in press.
178. Lisman T, Porte RJ. Mechanisms of platelet-mediated liver regeneration. *Blood* 2016, 128(5):625-9.
179. Potze W, Siddiqui MS, Boyett SL, Adelmeijer J, Daita K, Sanyal AJ, Lisman T. Preserved hemostatic status in patients with non-alcoholic fatty liver disease. *J. Hepatol* 2016, 65(5):980-987.
180. Lisman T. Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis. *Semin Thromb Haemost* 2016, in press.
181. Potze W, Sanyal AJ, Lisman T. Reply to: "Procoagulant imbalance in patients with non-alcoholic fatty liver disease". *J Hepatol* 2016, in press.
182. Lisman T, Violi F. Cirrhosis as a risk factor for venous thrombosis. *Thromb Haemost* 2016, in press
183. Lisman T, Porte RJ. Value of Preoperative Hemostasis Testing in Patients with Liver Disease for Perioperative Hemostatic Management. *Anesthesiology* 2016, in press.

Books, or contributions to books

1. Lisman T, de Groot P.G. Hemostatic dysfunction related to liver diseases and liver transplantation. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. *Williams Hematology*, 7th edition. New York: McGraw-Hill Medical, 2006, Chapter 120: 1953-1958.
2. Lisman T, de Groot P.G. Hemostatic dysfunction related to liver diseases and liver transplantation. In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds. *Williams Hematology*, 8th edition. New York: McGraw-Hill Medical, 2010, Chapter 129: 2095-2100.
3. Lisman T, Porte RJ. Hepatic artery diseases. In: *Molecular pathology of liver diseases*. SPS Monga, editor, Springer, 2011, Chapter 47: 701-708.
4. Hendriks, H. G. D., Lisman, T. and Porte, R. J. (2012) Coagulation and Blood Transfusion Management. In: *Medical Care of the Liver Transplant Patient*, 4th edition (eds P.-A. Clavien and J. F. Trotter), Chapter 25, Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444398441.ch25
5. Arshad F, Lisman T, Porte RJ. Massive Blood Loss and Transfusion. *Liver Anesthesiology and Critical Care Medicine*, G Wagener, editor, Springer, 2012, Chapter 14: 169-180.
6. Lisman T, Porte RJ. Understanding and managing the coagulopathy of liver disease. In: *Consultative Hemostasis and Thrombosis*, 3rd edition, Kitchens, Alving, Kessler, eds, Saunders Elsevier 2013, Chapter 38: 688-697.
7. Lisman T, Porte RJ. Hemostatic problems in chronic and acute liver disease. "Hemostasis and Thrombosis: Current Guidelines in Clinical Management". Roberts and Saba, eds, Wiley 2014, Chapter 20: 271-283.
8. Leebeek F.W.G., Lisman T. Hemostatic dysfunction related to liver diseases and liver transplantation. In: Kaushanski K, Lichtmann MM, Kipps TJ, Prchal JT, Levi M, Press O, Burns L, eds. *Williams Hematology*, 9th edition. New York: McGraw-Hill Medical, 2016, Chapter 128: 2191-2109.
9. Lisman T. Platelets and liver disorders. In: Gresele P, Lopez JA, Kleinman NS, Page CP, eds. *Platelets in Thrombotic and Non-Thrombotic Disorders*. Cambridge University Press, 2017, in press.
10. Lisman T, Porte RJ. Understanding and managing the coagulopathy of liver disease. In: *Consultative Hemostasis and Thrombosis*, 4th edition, Kitchens, Alving, Kessler, eds, Saunders Elsevier 2017, in press.

Invited lectures

2017

- Post-ASH meeting, Oldenburg, Germany (25 Jan) – “Haemostasiology”
- 1st International Conference on Fatty Liver, Seville, Spain (June 1-3) – “Coagulation in non-alcoholic fatty liver disease”
- 7th Biennial International Symposium on Women’s Health Issues in Thrombosis and Haemostasis, Barcelona, Spain (March 3-5) – “Liver disease in pregnancy”

2016

- Visiting professor lecture, Department of Pharmacology & Toxicology, Michigan State University, East Lansing, MI (Jan 26) – “Bleeding and Thrombosis in Patients with Liver diseases”
- Symposium on Coagulation and Portal Hypertension, University Hospital “Inselspital”, Bern, Switzerland (May 12th) – “Treating chronic liver disease with anticoagulants: rationale and pitfalls”
- 62nd Annual SSC Meeting Montpellier, France (May 27) “Haemostasis in Liver Failure and/or Liver Regeneration”
- 21st Congress of the European Haematology Association, Copenhagen, Denmark (June 9 – 12) – “Haemostasis and thrombosis in patients with liver disease”
- 3rd Maastricht Thrombin Summer School, Maastricht, The Netherlands (June 17) – “Thrombin generation in kidney and liver disease”
- Coimbra Liver Transplantation Conference (9-10 Sept) – “Haemostasis Management of the Critically Ill Cirrhotic Patient”, “Systemic and Local Thrombosis - Late Events After Successful Transplant”, and “New Anticoagulant Drugs”
- 3rd Congress on Controversies in Thrombosis and Hemostasis (CiTH) Moscow, Russia – (October 20-22, 2016) – “Hemostasis in patients with liver diseases”
- ISTH Advanced Training Course Emory University, Atlanta, Georgia, USA (November 1-4) – “Current concepts of the coagulation system” and “Hemostasis in patients with impaired liver function”
- Biannual symposium of the External quality Control of diagnostic Assays and Tests association, Leiden, The Netherlands (Nov 11th). “The relevance of pre-operative screening”
- American Association for The Study of Liver Disease Annual Meeting, Boston, USA (Nov 13th) – Special Interest Group on Hypercoagulability in Cirrhosis: From the Sinusoid to the Portal Vein – “Cirrhosis as a Prothrombotic State: Overview and Update”
- 11th Senior Trainee Clotters Meeting, Birmingham, UK (Nov 24-25) – “Managing coagulation in liver disease”
- 10th Innsbruck Winter Symposium for Coagulation, Innsbruck, Austria (Dec 15-16) – “Coagulation in liver failure – still balanced?”

2015

- Eighth UK Bayer HealthCare Expert Clotters Meeting Birmingham, UK (23-25 Jan) – “Recombinant VIIa in haemophilia: how does it work?”
- 5th International Symposium on Critical Bleeding in Copenhagen, Denmark (Aug 31st -1st. Sept) – “Coagulopathy in the ICU and multiorgan failure” and “NOACs in hepatic failure - Is there a problem?”
- Coagulation in Liver Disease Symposium VI Discussion, Debates, and Deliberations (Oct 3 & 4), Charlottesville, VA – “Fibrinolysis in cirrhosis” and “Beyond thrombin generation: alterations in fibrin structure in cirrhosis”
- Pfizer-Sponsored 2015 Global Haemophilia Summit – Managing Haemophilia for Life, Prague, Czech Republic (Sept 25th and 26th) – “Coagulation and liver disease: effective assessment and optimal management”
- 2nd Congress on Controversies in Thrombosis & Hemostasis (CiTH), Barcelona, Spain (November 5-7) – “Management of hemostasis during invasive procedures in patients with cirrhosis “
- Combined meeting of the British Society for Haemostasis and Thrombosis, Anticoagulation UK and NEQAS, London, UK (Nov 12th and 13th) – “Bleeding and Thrombosis in patients with liver disease”
- Dutch Transplant Society Meeting (Nov 19th) – “Risk and benefits of heparin/LMWH in immediate post-transplant phase”

2014

- Stockholm Liver Week, Stockholm, Sweden (4-7 Feb) – “The balance of hemostasis in liver disease”

- EASL & Vascular Liver Disease Group joint workshop of the EASL International Liver Congress 2014, London, UK (9-13 Apr) – “New anticoagulants: Pro and cons in liver patients”
- Joint conference of the ILTS, ELITA and LICAGE (4-7 June) – “Understanding the coagulopathy of acute liver failure”
- Current Topics in Intermediate and Intensive Care of Centro Hospitalar do Porto (CHP) – Hospital Sto António (23 June) - “Coagulopathy in ALF: different from cirrhosis = different support?”
- 20e AMSTOL symposium (19 Sept) – “Liver & Coagulation”
- Congress on Controversies in Thrombosis & Hemostasis (CiTH), Berlin, Germany (30 Oct-2 Nov) – “Prevention and treatment of bleeding in liver disease - should hemostatic agents be used? “
- Visiting professor Klinik für Allgemein-, Viszeral- Transplantationschirurgie Universitätsklinikum Essen, Germany (Dec 8) – “The role of platelets in cirrhosis”
- EASL MASTERCLASS, Champéry, Switzerland (Dec 11 – 13) – “Coagulation in liver disease”

2013

- 6th UK Expert Clotters Meeting, Birmingham, UK (17-18 Jan) – “Rebalanced hemostasis in patients with liver disease”
- 24th Congress of the International Society on Thrombosis and Haemostasis, Amsterdam, The Netherlands (June 29-July 4) – “Clotting or bleeding in liver disease”
- International Symposium on Critical Bleeding, Copenhagen, Denmark (2-3 Sept) – “Hepatic and renal failure induced coagulopathy and bleeding”
- Meeting of the Liver Intensive Care Group of Europe (LICAGE), Essen, Germany (5-6 Sept) - "Role of platelet transfusion in liver transplantation“
- 5th symposium on Hemostasis in Liver Disease, Padua, Italy (27-28 Sept) – “New anticoagulants”
- 45th Advances in Haematology Course, London, UK (Oct 16) – “The complex coagulopathy of liver disease”
- Visiting lecturer, Division of Gastroenterology and Hepatology, Center for Coagulation Disorders in Liver Disease, University of Virginia, Charlottesville, VA, USA (Oct 31) – “Bleeding and thrombosis in liver disease: prevent, treat, ignore?”
- 28th Erasmus Liver Day, Rotterdam, NL (Nov 28) - "Prevention and management of portal vein thrombosis in cirrhosis"
- Annual meeting of the Belgian Society of Thrombosis and Hemostasis (Nov 28-29) – “Coagulation and liver diseases : new insights”

2012

- Postgraduate School of Gastroenterology, University of Padua, Italy (March 20th) – “platelet function in liver disease”
- AASLD Clinical Symposium as part of the Digestive Disease Week, San Diego, USA (May 22). - Coagulopathy in Cirrhosis: Toward an Understanding of the Bleeding Diathesis
- Instrumentation Laboratories Science Symposium 2012, Utrecht, The Netherlands (May 31st) “Hemostatic abnormalities in patients with Liver Disease”
- EASL monothematic conference “Vascular diseases of the Liver”, Talinn, Estonia (June 22-23) – “Monitoring anticoagulation in patients with liver disease”
- 21st International Congress on Fibrinolysis and Proteolysis, Brighton, UK (July 1-5) – “Fibrinolysis in patients with liver disease”
- Visiting Lecturer University of Calgary Liver group, Canada (Oct 18th) - “The coagulopathy of cirrhosis: time for a paradigm change”
- Visiting Lecturer University of Edmonton Dept. Gastroenterology, Canada (Oct 29th) – “Rebalanced hemostasis in patients with liver disease”

2011

- 4th symposium on Hemostasis in Liver Disease, London (sept 30-oct 1st) – “Platelets in liver disease”
- Symposium of the Dutch Society on Thrombosis and Hemostasis, Koudekerke, The Netherlands (May 17th) – Keynote lecture: “Hemostasis and liver disease”
- Roche science symposium 2011, Houten, The Netherlands (April 7th) – “Perioperative bloodloss”
- 2nd International symposium on 'Transparency in Transfusion Medicine', Zwolle, The Netherlands (April 15-16) – “Platelets – from theory to therapy”
- Behring Advisory Board, London, UK (February 11th) – “PCC’s in liver disease”

2010

- Transplant forum, University Hospital St. Luc, Brussels, Belgium (Sept 20th 2010) – “Haemostasis and liver transplantation – new insights”
- 5th symposium on hemostasis with special focus on factor VIIa & tissue factor: from cell biology to animal models, Chapel Hill, NC, USA (April 30th – May 1st) – “FVIIa interaction with platelets”.
- 1st joint meeting GTH & NVTH, Neurenberg, Germany (February 24th – February 26th) – “Fibrinolysis and the risk of thrombosis”

2009

- 3rd symposium on Hemostasis in Liver Disease, Groningen, The Netherlands (sept 18/19^l) – “Compensatory hemostatic mechanisms in patients with liver disease”
- European Liver and Intestine Transplant Association postgraduate course, Paris, France (Aug 30th) – “The hepatic artery in liver transplantation”.
- Inflammatory Cardiomyopathy, Molecular pathogenesis and therapy Summer School, Tübingen, Germany (July 3-4) – “The role of platelets in liver inflammation and regeneration”

2008

- Bootcongres, Zeewolde, Netherlands (March 26-28) – “Bloedstolling en ontsteking”
- 9th European Transplant Fellow Workshop (Sept 19-21) – “Interaction between coagulation and the immune system in organ transplantation”
- Stollingssymposium Stichting Kwaliteitsbevordering Stollingsonderzoek, Apeldoorn, Netherlands (Oct 30th) – “Toepassing en werkingsmechanisme van recombinant factor VIIa”
- Erasmus MC Hematology lectures, Rotterdam, The Netherlands (Nov 17th) – “Novel ligands of the platelet receptor glycoprotein Iba”
- Wintermeeting of the Belgian Association for the Study of the Liver (BASL), Brussels, Belgium (December 12th) – “Hemostasis in liver diseases”.
- European Association for the Study of the Liver School of Hepatology, Leuven, Belgium (December 12-13) – “Thrombosis and the Liver”

2007

- Dept. of Hematology, Hospital Clinic, Barcelona, Spain (Oct 9-10) – “Novel ligands of glycoprotein Iba”
- 53rd Meeting of the Scientific and Standardisation Committee of the International Society of Thrombosis and Haemostasis, Geneva, Switzerland (July 6-7) – “Hypofibrinolysis as a risk factor for venous and arterial thrombosis”
- 2nd symposium on Hemostasis in Liver Disease, Charlottesville, VA, USA (April 28-29) – “The platelet and liver disease”

2006

- 10th anniversary meeting of NovoSeven in the Nordic countries, Copenhagen, Denmark (October 18th) – “Recombinant factor VIIa and platelets *relevance for mechanism of action*”
- Gordon Conference on Hemostasis, Waterville, ME, USA (July 9-14) – “Hypofibrinolysis as a risk factor for venous thrombosis”
- Bloodless liver surgery – conference of the European Postgraduate Gastro Surgical School (Feb 2nd) – “The liver and hemostasis”

2005

- 1st symposium on Hemostasis in Liver Disease, Charlottesville, VA, USA (Oct 9-10) – “Risk-benefit of different agents”
- Dept. of Biochemistry, University of Cambridge, UK (July 6th) – “Identification of von Willebrand factor binding sites in collagen type III using triple helical peptides”

2004

- Annual meeting of the Belgian Society of Thrombosis and Haemostasis, Brussels, Belgium (Nov 23rd) – “Mechanism of action of rFVIIa in patients with Glanzmann Thrombasthenia”
- Annual meeting of the German Hemostasis Society, Frankfurt, Germany (July 23rd) – “New insights into the mechanism of action of rFVIIa in thrombocytopathy”

- Novo Nordisk European Symposium, Madrid, Spain (April 23-24) – “Mechanism of action of recombinant factor VIIa *Focussed on the use in patients with Glanzmann Thrombasthenia*”

2003

- Royal Academy Colloquium on Thrombin Generation, Amsterdam, The Netherlands (March 26-29) – “Thrombin generation and fibrinolysis” and “The effects of thrombin generation on platelet deposition under flow conditions”

2002

- 1st Symposium on Haemostasis with a special focus on factor VIIa and tissue factor, Chapel Hill, NC, USA (April 4-6) – “Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A, but not in plasma from patients with liver cirrhosis”

2001

- XIVth van Creveld Symposium on Haemophilia, Amersfoort, The Netherlands. (Oct 12th) – “Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A”
- 6th Novo Nordisk symposium on Treatment of Bleeding- and Thrombotic disorders, Copenhagen, Denmark (3-4 May) – “Tissue factor-independent thrombin formation via recombinant factor VIIa restores adhesion of α IIb β 3 deficient platelets to endothelial cell matrix under flow conditions”